

To: [REDACTED] [REDACTED]@rivm.nl]
From: [REDACTED] [JACNL]
Sent: Fri 1/29/2021 9:39:16 PM
Subject: Persbericht interim analyse fase 3 studie ENSEMBLE met COVID-19 vaccin-kandidaat Janssen
Received: Fri 1/29/2021 9:39:29 PM
[FINAL COVID-19 Ph3ToplineData PR_012921.pdf](#)

Dag [REDACTED]

Wellicht heb je het nieuws al gezien. Voor de volledigheid stuur ik je hierbij het persbericht van Johnson & Johnson dat vanmiddag is uitgegaan over de interim analyse van de eerste fase 3 studie met het Janssen COVID-19 vaccin, ENSEMBLE.

Als je vragen hebt naar aanleiding van dit bericht, laat het me graag weten.

Met vriendelijke groeten, [REDACTED]

[REDACTED]

[REDACTED]



Janssen-Cilag B.V.
Graaf Engelbertlaan 75, 4837 DS Breda
Postbus 4928, 4803 EX Breda
Phone +31 [REDACTED]
Mobile +31 [REDACTED]
[REDACTED]@its.jnj.com

Website: www.janssen.com/nederland

Twitter: [@Janssen_Ned](#) | Facebook: [Janssen Nederland](#) | LinkedIn: [Janssen Nederland](#)

Confidentiality Notice: This e-mail transmission is confidential and may be privileged information that is intended only for the individual or entity named in the e-mail address. If you are not the intended recipient and believe you have received this e-mail transmission in error, please reply to the sender, so that we can arrange for proper delivery, and then please delete the message from your inbox. The unauthorized use, dissemination, distribution or reproduction of this e-mail, including attachments, is prohibited and may be unlawful. Receipt by anyone other than the intended recipient(s) is not a waiver of any attorney/client or other privilege. Thank you.